KBI BIOPHARMA

SUREmAb™

Monoclonal Antibody Development, the Way it's Meant to Be

Simple, secure, and streamlined from cell line development (CLD) to drug substance release

SUREmAb™ preemptively navigates technical hurdles for exceptional performance, delivering high titers (up to 10 g/L) with a streamlined, lower-cost workflow. Thanks to this preset offer, your simple mAb development is made SURE, while accelerating timelines and maximizing ROI.

- Efficient processes for high titers and exceptional yield
- Drug substance release in as little as 11 months
- Transfection to high-performing RCB in as little as 9 weeks
- Innovation with alleviation of royalties when you manufacture with KBI Biopharma

Join a Legacy of Success

SUREmAb™ is built on the power of our SUREtechnology Platform™ powered by Selexis®

15+

Years of mAb Development Experience

150+

Therapeutic mAb Projects

7

Commercialized mAb Therapeutics

SUREmAb™: Research Cell Bank (RCB) Generation, Simplified



SUREmAb™: Transition to Manufacturing, Streamlined



Figure 1: SUREmAb™ provides similar performance to regular SUREtechnology Platform™ process

Fig. 1 - SUREmAb™ compared to regular SUREtechnology Platform™ process. Titer profile of twelve RCB cell lines expressing an IgG1 produced in Ambr® 15 using SUREmAb™ platform in blue and SUREtechnology Platform™ in orange. Straight line represents the average value and the bands represent the SD of the twelve RCB cell lines.

Figure 2: SUREmAb™ provides robust cell lines shown to be scalable

Fig. 2 - SUREmAb™ scalability. VCD, viability (a) and productivity (b) profiles of one stable RCB expressing an IgG1 in 3 different scales: Ambr® 15, 3L and 200L bioreactors. Two chemically defined media were used: standard industry medium 1 (straight lines) and CHO-optimized medium CELLiST™ Basal CHO MX (dotted line).





Global Compliance Local Presence

Click the button to learn more about SUREmAb™

Learn More

Please note: The SUREmAb offer does not apply to mAb-based biosimilar projects or for any IgG shape-derived proteins that are different from an intact IgG format - including bsAbs, Fc fusions, and IgG fragments - as well as other protein classes outside of IgGs. Timeline estimates are subject to open manufacturing capacity and may vary by project.

KBI BIOPHARMA

A JSR Life Sciences Company